TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 1546839

Group type: EXPERIMENTAL
Intervention: Methacholine challenge test (maximum dose of 12.25 mumol)
Number of subjects: 225

Group type: EXPERIMENTAL
Intervention: PEF variability (measured as mean daily maximum amplitude as a percentage of the mean)
Number of subjects: 225

Group type: EXPERIMENTAL
Intervention: Bronchial reactivity
Number of subjects: 225

Group type: EXPERIMENTAL
Intervention: Both bronchial reactivity and PEF variability
Number of subjects: 225
Study: 2866784

Group type: EXPERIMENTAL
Intervention: Temazepam (20 mg)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Nitrazepam (10 mg)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study: 29990271

Group type: EXPERIMENTAL
Intervention: Novel lightweight incremental quantile estimator
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Deterministic updates with adjusted step size
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Single parameter tuning
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Multiplicative algorithm
Number of subjects: 0
Study: 30244217

Group type: EXPERIMENTAL
Intervention: Single intravenous infusion of tocilizumab
Number of subjects: 50

Group type: COMPARATOR
Intervention: Normal saline (placebo)
Number of subjects: 50
Study: 27037462

Group type: EXPERIMENTAL
Intervention: Long-interval misoprostol (2 tablets of 400 μg at 12 hours and 2 placebo tablets at 3 hours before procedure)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Short-interval misoprostol (2 placebo tablets at 12 hours and 2 tablets of 400 μg at 3 hours before procedure)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Long-interval misoprostol
Number of subjects: 120

Group type: COMPARATOR
Intervention: Short-interval misoprostol
Number of subjects: 120
Study: 24871547

Group type: EXPERIMENTAL
Intervention: Memantine
Number of subjects: 41

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 41
Study: 22930699

Group type: EXPERIMENTAL
Intervention: Donepezil 23 mg/d
Number of subjects: 0
Study: 20662877

Group type: EXPERIMENTAL
Intervention: TENS at 3 pps
Number of subjects: 35

Group type: COMPARATOR
Intervention: TENS at 80 pps
Number of subjects: 35
Study: 18569681

Group type: EXPERIMENTAL
Intervention: Difficult divided attention task during learning and test phases (Experiment 1)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Manipulated encoding time and collected remember-know judgements (Experiment 2)
Number of subjects: 0
Study: 16145024

Group type: EXPERIMENTAL
Intervention: Internet-based CME intervention
Number of subjects: 97

Group type: COMPARATOR
Intervention: Live, small-group, interactive CME workshop
Number of subjects: 97
Study: 11810088

Group type: EXPERIMENTAL
Intervention: Sublingual misoprostol (50 microg, repeated every 4 hours to a maximum of 5 doses)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Sublingual misoprostol
Number of subjects: 100

Group type: COMPARATOR
Intervention: Oral misoprostol (50 microg, repeated every 4 hours to a maximum of 5 doses)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 100
Study: 10513854

Group type: EXPERIMENTAL
Intervention: Paroxetine (mean dose = 24.5 mg/day)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Nortriptyline (mean dose = 51.3 mg/day; mean blood level = 85.5 ng/mL)
Number of subjects: 40
Study: 7491235

Group type: EXPERIMENTAL
Intervention: RRV-S1 vaccine (4 x 10(4) plaque-forming units)
Number of subjects: 989

Group type: EXPERIMENTAL
Intervention: RRV-TV vaccine (4 x 10(4) plaque-forming units)
Number of subjects: 989

Group type: EXPERIMENTAL
Intervention: RRV-S1 vaccine
Number of subjects: 989

Group type: EXPERIMENTAL
Intervention: RRV-TV vaccine
Number of subjects: 989

Group type: EXPERIMENTAL
Intervention: Both vaccines
Number of subjects: 989
Study: 1834395

Group type: COMPARATOR
Intervention: Immediate-release disopyramide (400 mg/day)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Slow-release disopyramide (500 mg/day)
Number of subjects: 12
Study: 6344610

Group type: EXPERIMENTAL
Intervention: Experimental diet (65% carbohydrate, 20% fat, 15% protein for 6 weeks)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Control diet (45% carbohydrate, 40% fat, 15% protein for 4 weeks)
Number of subjects: 6
Study: 31778458

Group type: EXPERIMENTAL
Intervention: 3 times/week training (EG1)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: 2 times/week training (EG2)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 40
Study: 28888358

Group type: EXPERIMENTAL
Intervention: 1-year extension of early intervention (EI)
Number of subjects: 160

Group type: COMPARATOR
Intervention: step-down psychiatric care
Number of subjects: 160
Study: 25350500

Group type: EXPERIMENTAL
Intervention: Burdock root tea (3 cups daily, each cup containing 2 g/150 mL boiled water)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Control group (3 cups of 150 cc boiled water daily)
Number of subjects: 36
Study: 25707081

Group type: EXPERIMENTAL
Intervention: Chew 2 pieces of sugar-free gum for 20 minutes, 3x per day
Number of subjects: 177

Group type: EXPERIMENTAL
Intervention: Chew 2 pieces of sugar-free gum for 12 minutes, 5x per day
Number of subjects: 177

Group type: COMPARATOR
Intervention: No gum
Number of subjects: 177
Study: 23236367

Group type: EXPERIMENTAL
Intervention: Single-dose albendazole during pregnancy
Number of subjects: 2016

Group type: EXPERIMENTAL
Intervention: Quarterly single-dose albendazole during childhood
Number of subjects: 2016

Group type: COMPARATOR
Intervention: Placebo during pregnancy
Number of subjects: 2016

Group type: COMPARATOR
Intervention: Placebo during childhood
Number of subjects: 2016
Study: 20411695

Group type: EXPERIMENTAL
Intervention: Sleep restriction therapy plus hypnotic withdrawal (SR+HW)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Sleep hygiene education (SHE)
Number of subjects: 46
Study: 17704347

Group type: EXPERIMENTAL
Intervention: DHEA (50 mg daily for 12 weeks)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 15725695

Group type: EXPERIMENTAL
Intervention: Fluvastatin (20 mg/d)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Pravastatin (10 mg/d)
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Fluvastatin (20 mg/d) after crossover to Pravastatin
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Pravastatin (10 mg/d) after crossover to Fluvastatin
Number of subjects: 46

Group type: COMPARATOR
Intervention: Fluvastatin (20 mg/d) and Pravastatin (10 mg/d)
Number of subjects: 46
Study: 11943524

Group type: EXPERIMENTAL
Intervention: Sevoflurane-rapacuronium
Number of subjects: 40

Group type: COMPARATOR
Intervention: Propofol-rapacuronium
Number of subjects: 40
Study: 9808220

Group type: EXPERIMENTAL
Intervention: Proprietary mixture of 6 monoterpenes in olive oil
Number of subjects: 24

Group type: COMPARATOR
Intervention: Olive oil alone
Number of subjects: 24
Study: 8595682

Group type: EXPERIMENTAL
Intervention: Intramuscular meperidine (50 mg) in the deltoid
Number of subjects: 60

Group type: COMPARATOR
Intervention: Normal saline (NS) in the deltoid and NS in the wound (Control Group C)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Wound infiltration with meperidine (50 mg)
Number of subjects: 60
Study: 2653846

Group type: EXPERIMENTAL
Intervention: Radiotherapy + endocrine therapy
Number of subjects: 363

Group type: EXPERIMENTAL
Intervention: Radiotherapy + chemotherapy
Number of subjects: 363

Group type: EXPERIMENTAL
Intervention: Radiotherapy + endocrine therapy + chemotherapy
Number of subjects: 363

Group type: COMPARATOR
Intervention: Radiotherapy alone
Number of subjects: 363

Group type: EXPERIMENTAL
Intervention: Combination of hormone treatment and chemotherapy
Number of subjects: 363
Study: 1188710

Group type: EXPERIMENTAL
Intervention: Propranolol (60 mg)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 31594431

Group type: EXPERIMENTAL
Intervention: Intensive lifestyle intervention (1-year duration)
Number of subjects: 1561

Group type: COMPARATOR
Intervention: Weight regain (defined by 5 cut points: 0%, 25%, 50%, 75%, and 100%)
Number of subjects: 1561

Group type: EXPERIMENTAL
Intervention: Maintaining ≥75% of weight lost
Number of subjects: 1561
Study: 28499367

Group type: EXPERIMENTAL
Intervention: Long-needle acupuncture (LA)
Number of subjects: 77

Group type: COMPARATOR
Intervention: Traditional acupuncture (TA)
Number of subjects: 77
Study: 26093910

Group type: EXPERIMENTAL
Intervention: Active magnetic stimulation
Number of subjects: 120

Group type: COMPARATOR
Intervention: Sham magnetic stimulation
Number of subjects: 120
Study: 23017441

Group type: EXPERIMENTAL
Intervention: Fruit and vegetable purée-based drink (FVPD)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Fruit-flavoured sugar-matched control
Number of subjects: 24
Study: 21934690

Group type: EXPERIMENTAL
Intervention: Weekly docetaxel/gemcitabine followed by erlotinib (arm A)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Erlotinib followed by weekly docetaxel/gemcitabine (arm B)
Number of subjects: 100
Study: 19258618

Group type: EXPERIMENTAL
Intervention: Low molecular weight heparin
Number of subjects: 238

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 238

Group type: EXPERIMENTAL
Intervention: Overall
Number of subjects: 238
Study: 16961695

Group type: EXPERIMENTAL
Intervention: R137696 (1-2 mg)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study: 14753731

Group type: EXPERIMENTAL
Intervention: Ibandronate 2.5 mg
Number of subjects: 653

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 653
Study: 11426068

Group type: EXPERIMENTAL
Intervention: Lipopeptides (mixture of six NEF, GAG, and ENV lipopeptides)
Number of subjects: 28
Study: 9436691

Group type: EXPERIMENTAL
Intervention: 24 h period of bed rest (Group A)
Number of subjects: 182

Group type: COMPARATOR
Intervention: 20 min period of bed rest (Group B)
Number of subjects: 182
Study: 8273376

Group type: EXPERIMENTAL
Intervention: Oversewing plus vagotomy (O+V)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Gastric resection (GR)
Number of subjects: 120
Study: 3304021

Group type: EXPERIMENTAL
Intervention: High-frequency oscillatory ventilation (HFO-A) at 15 Hz for 12-203 hours
Number of subjects: 20

Group type: COMPARATOR
Intervention: Conventional mechanical ventilation (CMV)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: High-frequency oscillatory ventilation (HFO-A)
Number of subjects: 20
Study: 31857268

Group type: EXPERIMENTAL
Intervention: Antithrombotic medications (aspirin, clopidogrel)
Number of subjects: 347

Group type: COMPARATOR
Intervention: No antithrombotic medications
Number of subjects: 347

Group type: EXPERIMENTAL
Intervention: Anticoagulation medications
Number of subjects: 347
Study: 28943002

Group type: EXPERIMENTAL
Intervention: Extracorporeal shockwave therapy (ESWT)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Sham treatment
Number of subjects: 30
Study: 26150431

Group type: EXPERIMENTAL
Intervention: Cognitive‐behavioral coping skill training
Number of subjects: 64

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 64
Study: 24626851

Group type: EXPERIMENTAL
Intervention: Simeprevir 100 mg QD with peginterferon and ribavirin for 12 weeks (SMV12)
Number of subjects: 155

Group type: EXPERIMENTAL
Intervention: Simeprevir 100 mg QD with peginterferon and ribavirin for 24 weeks (SMV24)
Number of subjects: 155
Study: 22519735

Group type: EXPERIMENTAL
Intervention: Insulin Aspart
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: BIAsp70
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: BIAsp50
Number of subjects: 19

Group type: COMPARATOR
Intervention: Human Insulin
Number of subjects: 19
Study: 21046930

Group type: EXPERIMENTAL
Intervention: Q8003 (morphine/oxycodone 12/8 mg)
Number of subjects: 263

Group type: EXPERIMENTAL
Intervention: Q8003 (morphine/oxycodone 3/2 mg)
Number of subjects: 263

Group type: EXPERIMENTAL
Intervention: Q8003 (morphine/oxycodone 6/4 mg)
Number of subjects: 263

Group type: EXPERIMENTAL
Intervention: Q8003 (morphine/oxycodone 18/12 mg)
Number of subjects: 263

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 263
Study: 18304473

Group type: EXPERIMENTAL
Intervention: Adjuvant radiotherapy
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Combination of adjuvant radiotherapy with androgen deprivation therapy
Number of subjects: 28

Group type: COMPARATOR
Intervention: Surgical technique
Number of subjects: 28
Study: 15710219

Group type: EXPERIMENTAL
Intervention: i.v. mixed-micellar phylloquinone (vitamin K1) 10 mg
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: oral mixed-micellar phylloquinone (vitamin K1) 10 mg
Number of subjects: 49

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 49
Study: 14500804

Group type: EXPERIMENTAL
Intervention: Parathyroid hormone (1-84) 100 microg
Number of subjects: 238

Group type: EXPERIMENTAL
Intervention: Alendronate 10 mg
Number of subjects: 238

Group type: EXPERIMENTAL
Intervention: Combination therapy (Parathyroid hormone + Alendronate)
Number of subjects: 238
Study: 10663814

Group type: EXPERIMENTAL
Intervention: Tramadol bolus (1 mg/kg)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Tramadol continuous infusion (150 microg/kg per h)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Fentanyl continuous infusion (2 microg/kg per h)
Number of subjects: 42
Study: 9065133

Group type: EXPERIMENTAL
Intervention: Heparin and low-dose aspirin
Number of subjects: 50

Group type: COMPARATOR
Intervention: Low-dose aspirin
Number of subjects: 50
Study: 1381643

Group type: EXPERIMENTAL
Intervention: Teicoplanin
Number of subjects: 165

Group type: COMPARATOR
Intervention: Cephradine plus metronidazole
Number of subjects: 165
Study: 6140541

Group type: EXPERIMENTAL
Intervention: Nicotinic acid 2 g orally in divided doses
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Nicotinic acid 1 g orally in divided doses
Number of subjects: 62

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 62
Study: 29800322

Group type: EXPERIMENTAL
Intervention: Polyethylene skin wrapping for 1 hour
Number of subjects: 151

Group type: COMPARATOR
Intervention: Control group (warm cloth after initial care)
Number of subjects: 151
Study: 28158276

Group type: EXPERIMENTAL
Intervention: Fecal microbiota transplantation (FMT) for 6 days through a nasointestinal tube.
Number of subjects: 60

Group type: COMPARATOR
Intervention: Conventional treatment (education, behavioral strategies, and oral laxatives).
Number of subjects: 60
Study: 25998212

Group type: EXPERIMENTAL
Intervention: DA-3803 (test formulation)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Ovidrel(®) (reference formulation)
Number of subjects: 32
Study: 24360521

Group type: EXPERIMENTAL
Intervention: Grafted tubularized incised plate urethroplasty (G-TIP)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Tubularized incised plate urethroplasty (TIP)
Number of subjects: 50
Study: 22914365

Group type: EXPERIMENTAL
Intervention: AVX101 (alphavirus replicon HIV-1 subtype C gag vaccine)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 19634573

Group type: EXPERIMENTAL
Intervention: metformin + repaglinid (2 mg for each meal)
Number of subjects: 60

Group type: COMPARATOR
Intervention: metformin + glimepirid (3 mg in the morning)
Number of subjects: 60
Study: 18036303

Group type: EXPERIMENTAL
Intervention: Standardized Tertiary Rehabilitation (STR)
Number of subjects: 1365

Group type: COMPARATOR
Intervention: Routine interventions
Number of subjects: 1365
Study: 15631537

Group type: EXPERIMENTAL
Intervention: Olmesartan medoxomil 20 mg/day
Number of subjects: 0

Group type: COMPARATOR
Intervention: Losartan potassium 50 mg/day
Number of subjects: 0

Group type: COMPARATOR
Intervention: Valsartan 80 mg/day
Number of subjects: 0

Group type: COMPARATOR
Intervention: Irbesartan 150 mg/day
Number of subjects: 0
Study: 12092918

Group type: EXPERIMENTAL
Intervention: Prolonged exposure therapy
Number of subjects: 20
Study: 10546018

Group type: EXPERIMENTAL
Intervention: HRV analysis in diabetic children aged > or = 11 years
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: HRV analysis in younger diabetic patients
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: Illness duration and microalbuminuria
Number of subjects: 73
Study: 7496291

Group type: EXPERIMENTAL
Intervention: Treatment
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Meta-analysis of randomised trials
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cohort studies
Number of subjects: 0
Study: 2107112

Group type: EXPERIMENTAL
Intervention: Flexible sigmoidoscopy plus air contrast barium enema
Number of subjects: 380

Group type: COMPARATOR
Intervention: Colonoscopy
Number of subjects: 380
Study: 573222

Group type: EXPERIMENTAL
Intervention: beta-glycerophosphate
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: linoleic acid
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: purified soybean lecithin
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: soybean lecithin plus cholic acid
Number of subjects: 6
Study: 31947529

Group type: EXPERIMENTAL
Intervention: Capsinoids (9 mg daily for 3 months)
Number of subjects: 69

Group type: COMPARATOR
Intervention: Placebo (daily for 3 months)
Number of subjects: 69
Study: 30920398

Group type: EXPERIMENTAL
Intervention: Steroid injection
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Kinesio taping (KT)
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Both steroid injection and KT
Number of subjects: 84

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 84
Study: 28524341

Group type: EXPERIMENTAL
Intervention: Nitazoxanide 500 mg b.i.d., clarithromycin 500 mg b.i.d., and omeprazole 40 mg b.i.d. for 14 days
Number of subjects: 224

Group type: COMPARATOR
Intervention: Metronidazole 500 mg b.i.d., clarithromycin 500 mg b.i.d., and omeprazole 40 mg b.i.d. for 14 days
Number of subjects: 224
Study: 25881035

Group type: EXPERIMENTAL
Intervention: Public reporting of prescribed ranking information
Number of subjects: 600

Group type: COMPARATOR
Intervention: Control group (no public reporting)
Number of subjects: 600
Study: 24034910

Group type: EXPERIMENTAL
Intervention: Nasal Intermittent Positive Pressure Ventilation (NIPPV)
Number of subjects: 62

Group type: COMPARATOR
Intervention: Nasal Continuous Positive Airway Pressure (NCPAP)
Number of subjects: 62
Study: 21525158

Group type: EXPERIMENTAL
Intervention: Intensive lifestyle intervention
Number of subjects: 3346

Group type: EXPERIMENTAL
Intervention: Metformin
Number of subjects: 3346

Group type: COMPARATOR
Intervention: Baseline levels
Number of subjects: 3346
Study: 19038501

Group type: EXPERIMENTAL
Intervention: Glucose infusion (4.5mg/kg/min, 2300-0700h)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Saline infusion (control)
Number of subjects: 20
Study: 16575410

Group type: EXPERIMENTAL
Intervention: Prone positioning (P)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Non-posturing (NP)
Number of subjects: 41
Study: 14991313

Group type: EXPERIMENTAL
Intervention: IOL implantation (intraocular lens implantation)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (seniors without cataract surgery)
Number of subjects: 0
Study: 11801830

Group type: EXPERIMENTAL
Intervention: 5% albumin
Number of subjects: 40

Group type: COMPARATOR
Intervention: Normal saline
Number of subjects: 40
Study: 9525985

Group type: EXPERIMENTAL
Intervention: GLP-1 at 0.3 pmol . kg‐1 . min‐1 + ex(9‐39)NH2 at 30 pmol . kg‐1 . min‐1
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: GLP-1 at 0.3 pmol . kg‐1 . min‐1 + ex(9‐39)NH2 at 60 pmol . kg‐1 . min‐1
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: GLP-1 at 0.3 pmol . kg‐1 . min‐1 + ex(9‐39)NH2 at 300 pmol . kg‐1 . min‐1
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: GLP-1 at 0.9 pmol . kg‐1 . min‐1 + ex(9‐39)NH2 at 300 pmol . kg‐1 . min‐1
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: ex(9‐39)NH2 at 300 pmol . kg‐1 . min‐1
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: GIP at 0.8 pmol . kg‐1 . min‐1 + ex(9‐39)NH2 at 300 pmol . kg‐1 . min‐1
Number of subjects: 6

Group type: COMPARATOR
Intervention: Saline
Number of subjects: 6

Group type: COMPARATOR
Intervention: GLP-1 at 0.3 pmol . kg‐1 . min‐1
Number of subjects: 6

Group type: COMPARATOR
Intervention: GLP-1 at 0.9 pmol . kg‐1 . min‐1
Number of subjects: 6
Study: 8306218

Group type: EXPERIMENTAL
Intervention: Heparinized saline (2 units/mL)
Number of subjects: 78

Group type: COMPARATOR
Intervention: Normal saline
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: Heparinized saline
Number of subjects: 78
Study: 2917588

Group type: EXPERIMENTAL
Intervention: Pindolol 5 mg
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Propranolol 80 mg
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study: 1098495

Group type: EXPERIMENTAL
Intervention: Oral rifampin (600 mg daily)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Oral dapsone (100 mg daily)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Intramuscular acedapsone (225 mg every 12 weeks)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Oral dapsone (50 mg daily)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: BL patients
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: LL patients
Number of subjects: 0
Study: 31416698

Group type: EXPERIMENTAL
Intervention: Intranasal atomization (INA) of medetomidine (40 μg kg‐1)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Intranasal drops (IND) of medetomidine (40 μg kg‐1)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Intramuscular (IM) injection of medetomidine (40 μg kg‐1)
Number of subjects: 18
Study: 28884566

Group type: EXPERIMENTAL
Intervention: Propofol medium-long chain lipid emulsion injection (100 mg initial dose, then 0.54 mg/kg/h for 24 hours)
Number of subjects: 87

Group type: COMPARATOR
Intervention: Control group (no sedative measures)
Number of subjects: 87
Study: 23812665

Group type: EXPERIMENTAL
Intervention: PEERS intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Waitlist ASD group
Number of subjects: 0
Study: 23154587

Group type: EXPERIMENTAL
Intervention: Olmesartan add-on therapy
Number of subjects: 46

Group type: COMPARATOR
Intervention: Non-ARB group
Number of subjects: 46
Study: 21884874

Group type: EXPERIMENTAL
Intervention: Late high-degree atrioventricular block (HAVB) documented by continuous ECG monitoring occurring more than 3 weeks after AMI
Number of subjects: 286
Study: 19620917

Group type: EXPERIMENTAL
Intervention: Supplementary training (high-intensity sprint-training regime consisting of 7 to 15 repeats of badminton-specific sprints twice per week)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Supplementary training
Number of subjects: 12

Group type: COMPARATOR
Intervention: Regular training (4 2-hour sessions per week)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Regular training
Number of subjects: 12